公开(公告)号：US20190127479A1

公开(公告)日：2019-05-02

申请号：US16177239

申请日：2018-10-31

Applicant: Janssen Biotech, Inc.

Inventor： Tahamtan Ahmadi ,  Christopher Chiu ,  Ming Qi ,  Amy Sasser ,  Jordan Schecter

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/573 ,  A61K31/4439 ,  A61K31/69 ,  A61K9/00 ,  A61K39/395

Abstract: Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.

公开(公告)号：US11618787B2

公开(公告)日：2023-04-04

申请号：US16177239

申请日：2018-10-31

Applicant: Janssen Biotech, Inc.

Inventor： Tahamtan Ahmadi ,  Christopher Chiu ,  Ming Qi ,  Amy Sasser ,  Jordan Schecter

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K31/573 ,  A61K31/495 ,  A61K31/4439 ,  A61K31/69 ,  A61K9/00 ,  A61K31/454 ,  A61K39/00

Abstract: Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.

公开(公告)号：US20230340145A1

公开(公告)日：2023-10-26

申请号：US18175345

申请日：2023-02-27

Applicant: Janssen Biotech, Inc.

Inventor： Tahamtan Ahmadi ,  Christopher Chiu ,  Ming Qi ,  Amy Sasser ,  Jordan Schecter

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/573 ,  A61K31/4439 ,  A61K31/69 ,  A61K39/395 ,  A61K9/00 ,  A61K31/454

CPC classification number: C07K16/2896 ,  A61P35/00 ,  A61K31/573 ,  A61K31/4439 ,  A61K31/69 ,  A61K39/3955 ,  A61K9/0019 ,  A61K31/454 ,  C07K2317/34 ,  C07K2317/565 ,  A61K2039/54

Abstract: Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.